Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Lifted by ARK Investment Management LLC

ARK Investment Management LLC raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,536,386 shares of the company’s stock after purchasing an additional 280,946 shares during the quarter. Intellia Therapeutics makes up approximately 1.2% of ARK Investment Management LLC’s holdings, making the stock its 25th biggest position. ARK Investment Management LLC owned about 12.31% of Intellia Therapeutics worth $146,174,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTLA. Blue Trust Inc. grew its stake in Intellia Therapeutics by 182.7% in the third quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock valued at $94,000 after purchasing an additional 2,707 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Intellia Therapeutics by 72.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,537 shares of the company’s stock valued at $401,000 after purchasing an additional 8,204 shares in the last quarter. SteelPeak Wealth LLC purchased a new position in Intellia Therapeutics in the third quarter valued at about $393,000. Finally, Harbor Capital Advisors Inc. grew its stake in Intellia Therapeutics by 71.0% in the third quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock valued at $1,628,000 after purchasing an additional 32,893 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $10.71 on Wednesday. The stock has a 50-day simple moving average of $10.99 and a 200 day simple moving average of $15.87. The stock has a market capitalization of $1.09 billion, a PE ratio of -1.97 and a beta of 1.80. Intellia Therapeutics, Inc. has a twelve month low of $8.96 and a twelve month high of $34.87.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of recent research reports. Oppenheimer lowered their target price on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Barclays reduced their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.71.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 29,000 shares of company stock valued at $352,551 in the last quarter. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.